Fig. 5From: Altered levels of CSF proteins in patients with FTD, presymptomatic mutation carriers and non-carriersCharacterization of VGF, NPTXR, TMEM132D,PDYN, NF-M and TN-R CSF levels in the second cohort. Significant differences between FTD patients and healthy individuals were replicated for (a) neurosecretory protein VGF (VGF), (b) neuronal pentraxin receptor (NPTXR), (c) transmembrane protein 132D (TMEM132D), (d) prodynorphin (PDYN), (e) neurofilament medium polypeptide (NF-M) and (f) tenascin-R (TN-R). Additional differences between FTD and AD was found for TN-R and NF-M (HPA023138, not shown in the figure). Stars indicate significant differences, * p < 0.05 and **p < 0.01. Control – healthy individuals, FTD – patients with frontotemporal dementia, AD – patients with Alzheimer’s diseaseBack to article page